I-Team investigator Adam Walser is now hearing from a woman with a rare blood disorder, who contacted us to tell us about her challenges.

Bristol-Myers Squibb acquires 2seventy bio for $286M, marking the end of a once-promising biotech. Check out if this is a ...

Vertex Pharmaceuticals demonstrates resilience with robust CF franchise, new approvals, and diversification efforts. Read why ...

Agios is advancing a robust clinical pipeline of investigational medicines with programs in alpha- and beta-thalassemia, sickle cell disease, pediatric PK deficiency, myelodysplastic syndromes ...

Agios is advancing a robust clinical pipeline of investigational medicines with programs in alpha- and beta-thalassemia, sickle cell disease, pediatric PK deficiency, myelodysplastic syndromes ...

Equities research analysts at Wedbush upped their Q1 2025 earnings per share estimates for Beam Therapeutics in a research note issued on Monday, March 10th. Wedbush analyst D. Nierengarten now ...

This is potentially the first therapy for both alpha and state thalassemia patients, the first oral therapy for the disease, the first treatment to demonstrate quality of life improvement for non ...

We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...

Editas Medicine, Inc.’s EDIT share price has surged by 16.48%, which has investors questioning if this is right time to sell.

The US pharmaceutical sector is experiencing a distinct trend never seen before with large American pharma companies continually looking for medicines in China.

Beam Therapeutics (NASDAQ:BEAM – Get Free Report)‘s stock had its “buy” rating reissued by research analysts at HC Wainwright ...